# Conbercept in Choroidal Neovascularization Secondary to Uveitis

> **NCT02934841** · PHASE2 · UNKNOWN · sponsor: **Chongqing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Choroidal Neovascularization
- Uveitis

## Interventions

- **DRUG:** Conbercept
- **DRUG:** sham

## Key facts

- **NCT ID:** NCT02934841
- **Lead sponsor:** Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2018-03
- **Final completion:** 2018-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02934841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02934841, "Conbercept in Choroidal Neovascularization Secondary to Uveitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02934841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*